Nuchal Translucency-Based Screening

Clinical Obstetrics and Gynecology

Volumn 46, Issue 4, 2003, Pages 909-922

  Welch, Karlla K ^a   Malone, Fergal D ^a,b  

^a Columbia Presbyterian Medical Center ^*  (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANEUPLOIDY; CONFERENCE PAPER; CONGENITAL HEART DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DOWN SYNDROME; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HIGH RISK POPULATION; HUMAN; IMAGE QUALITY; PRENATAL DIAGNOSIS; RISK ASSESSMENT; SCREENING; SECOND TRIMESTER PREGNANCY; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; DOWN SYNDROME; FEMALE; HUMANS; NECK; PRACTICE GUIDELINES; PREGNANCY; PREGNANCY TRIMESTERS; PRENATAL DIAGNOSIS; ULTRASONOGRAPHY, PRENATAL;

EID: 0242594548     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200312000-00023     Document Type: Conference Paper

References (50)

1. Wald NJ, Densem JW, George L, et al. Prenatal Screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn. 1996;16:143-153.
2. Wald NJ, Kennard A, Hackshaw AK, et al. Antenatal screening for Down's syndrome. J Med Screen. 1997;4:181-246.
3. Malone FD, Berkowitz RL, Canick JA, et al. First trimester screening for aneuploidy: research or standard of care? Am J Obstet Gynecol. 2000;182:490-496.
4. Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn. 1998;18:511-523.
5. Hyett J, Perdu M, Sharland G, et al. Using fetal nuchal translucency to screen for major congenital heart defects at 10-14 weeks of gestation: population based cohort study. BMJ. 1999;318:81-85.
6. Souka AP, Krampl E, Bakalis S, et al. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol. 2001;18:9-17.
7. Gallagher PG, Mahoney MJ, Gosche JR. Cystic hygroma in the fetus and newborn. Semin Perinatol. 1999;23:341-356.
8. Von Kaisenberg CS, Brand-Saberi B, Jonat W, et al. Pathophysiology of increased nuchal translucency in chromosomally abnormal fetuses. Prenat Neonatal Med. 1999;431-440.
9. Snijders RJ, Noble P, Sebire N, et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet. 1998;352:343-356.
10. Haddow JE. Antenatal screening for Down's syndrome: where are we and where next? Lancet. 1998;352:336-337.
11. Nicolaides KH, Sebire NJ, Snijders RJ, et al. Down's syndrome screening in the UK. Lancet. 1996;47:906-907.
12. Cuckle H. Fetal nuchal translucency test for Down's syndrome. Lancet. 1997;350:1629-1630.
13. Nicolaides KH, Snijders RJ, Cuckle HS. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat Diagn. 1998;18:519-521.
14. Bindra R, Heath V, Liao A, et al. One-stop clinic for assessment of risk of Trisomy 21 at 11-14 weeks: a prospective study of 15,030 pregnancies. Utrasound Obstet Gynecol. 2002;20:219-225.
15. Wapner RJ. BUN Study Group. First trimester aneuploid screening: results of the NICHD multicenter study. Am J Obstet Gynecol. 2001;185:S70.
16. Crossley JA, Aitken DA, Cameron AD, et al. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study. Br J Obstet Gynaecol. 2002;109:667-676.
17. Penn PA. Advances in prenatal screening for Down syndrome: II first trimester testing, integrated testing, and future directions. Clin Chim Acta. 2002;324:1-11.
18. Pandya PP, Snijders RJ, Psara N, et al. The prevalence of non-viable pregnancy at 10-13 weeks of gestation. Ultrasound Obstet Gynecol. 1996;7:170-173.
19. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. N Engl J Med. 1999;341:461-467.
20. Wald NJ. First-trimester nuchal translucency screening. J Ultrasound Med. 2002;21:481-487.
21. Cuckle H. Time for a total shift to first-trimester screening for Down's syndrome. Lancet. 2001;358:1658-1659.
22. Hackshaw AK, Wald NJ. Assessment of the value of reporting partial screening results in prenatal screening for Down syndrome. Prenat Diagn. 2001;21:737-740.
23. Matias A, Gomes C, Flack N, et al. Screening for chromosomal abnormalities at 10-14 weeks: the role of ductus venosus blood flow. Ultrasound Obstet Gynecol. 1998;12:380-384.
24. Bilardo CM, Muller MA, Zikulnig L, et al. Ductus venosus studies in fetuses at high risk for chromosomal or heart abnormalities: relationship with nuchal translucency measurement and fetal outcome. Ultrasound Obstet Gynecol. 2001;17:288-294.
25. Zoppi MA, Putzolu M, Ibba RM, et al. Fetal Diagnosis Ther. 2002;17:52-57.
26. Antolin E, Comas C, Torrents M, et al. The role of ductus venosus blood flow assessment in screening for chromosomal abnormalities at 10-16 weeks of gestation. Ultrasound Obstet Gynecol. 2001;17:295-300.
27. Murta CG, Moron AF, Avila MA, et al. Application of ductus venosus Doppler velocimetry for the detection of fetal aneuploidy in the first trimester of pregnancy. Fetal Diagnosis Ther. 2002;17:308-314.
28. Mavrides E, Sairam S, Hollis B, et al. Screening for aneuploidy in the first trimester by assessment of blood flow in the ductus venosus. Br J Obstet Gynaecol. 2002;109:1015-1019.
29. Hecher K. Assessment of ductus venosus flow during the first and early second trimesters: what can we expect? Ultrasound Obstet Gynecol. 2001;17:285-287.
30. Cicero S, Curcio P. Papageorghious, et al. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet. 2001;358:1665-1667.
31. De Biasio PD, Venturini PL. Correspondence to the Editor. Lancet. 2002;359:1344.
32. Hyett J, Perdu M, Sharland G, et al. Increased nuchal translucency at 10-14 weeks of gestation as a marker for major cardiac defects. Ultrasound Obstet Gynecol. 1997;10:242-246.
33. Souka AP, Snijders RJ, Novakov A, et al. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation. Ultrasound Obstet Gynecol. 1998;11:391-400.
34. Zosmer N, Souter VL, Chan CS, et al. Early diagnosis of major cardiac defects in chromosomally normal fetuses with increased nuchal translucency. Br J Obstet Gynaecol. 1999;106:829-833.
35. Schwarzler P, Carvalho JS, Senat MV, et al. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population. Br J Obstet Gynaecol. 1999;1029-1034.
36. Mavrides E, Cobain-Sanchez F, Tekay A, et al. Limitations of using first-trimester nuchal translucency measurement in routine screening for major congenital heart defects. Ultrasound Obstet Gynecol. 2001;17:106-110.
37. Ghi H, Huggon IC, Zosmer N, et al. Incidence of major structural cardiac defects associated with increased nuchal translucency but normal karyotype. Ultrasound Obstet Gynecol. 2001;18:610-614.
38. Cuckle H. Down's syndrome screening in twins. J Med Screen. 1998;5:3-4.
39. Sebire NJ, Souka A, Skentou H, et al. Early prediction of severe twin-to-twin transfusion syndrome. Hum Reprod. 2000;15:2008-2010.
40. Haddow JE, Palomaki GE, Knight GJ, et al. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med. 1998;338:955-961.
41. Monni G, Zoppi MA, Ibba RM, et al. Results of measurement of nuchal translucency ultrasound before and after training. Lancet. 1997;350:1631.
42. Scott F, Boogert A, Sinosich M, et al. Establishment and application of a normal range for nuchal translucency across the first trimester. Prenat Diagn. 1996;16:629-634.
43. Kadir RA, Economides DL. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome. Ultrasound Obstet Gynecol. 1997;9:244-247.
44. Hackshaw AK, Wald NJ. Inaccurate estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening. Prenat Diagn. 2001;21:741-746.
45. Palomaki GE, Knight GJ, McCarthy J, et al. Maternal serum screening for Down syndrome in the United States: a 1995 survey. Am J Obstet Gynecol. 1997;176:1046-1051.
46. Egan JF, Kaminsky LM, DeRoche ME, et al. Antenatal Down syndrome screening in the United States in 2001: A survey of maternal-fetal medicine specialists. Am J Obstet Gynecol. 2002;187:1230-1234.
47. Canadian Early and Mid-Trimester Amniocentesis Trial (CEMAT). Randomized trial to assess safety and fetal outcome of early and midtrimester amniocentesis. Lancet. 1998;351:242-247.
48. Whittle M. Down's syndrome screening: where to now? Br J Obstet Gynaecol. 2001;108:559-561.
49. Vintzileos AM, Ananth CV, Smulian JC, et al. Cost-benefit analysis of prenatal diagnosis for Down syndrome using the British or the American Approach. Obstet Gynecol. 2000;95:577-583.
50. American College of Obstetricians and Gynecologists Committee on Genetics. First trimester screening for fetal anomalies with nuchal translucency. ACOG Committee Opinion number 233. Washington, DC: ACOG, 1999.